GlassScriptPhysician profile
Kevin Wietecha
NPI 1669450557
$127,336.98
in general payments reported to CMS, 2019-2025
45 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $37K · 2021: $14K · 2022: $32K · 2023: $8,405 · 2024: $6,952 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $2,455 · Travel and Lodging: $526 · Consulting Fee: $45.85 · Education: $24.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,301.00 |
| Food and Beverage | $2,455.28 |
| Travel and Lodging | $525.69 |
| Consulting Fee | $45.85 |
| Education | $24.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $85,041.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $25,052.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11,649.29 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $3,001.12 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $329.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $240.88 | 2019-2024 | Tepezza, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $156.90 | 2022-2025 | |
| Dexcom, INC. | $150.82 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $140.26 | 2019-2024 | |
| Corcept Therapeutics | $117.79 | 2019-2024 | Korlym |
| Insulet Corporation | $112.97 | 2019-2025 | Omnipod |
| Amarin Pharma, INC. | $103.01 | 2019-2022 | |
| Antares Pharma, INC. | $100.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.25 | 2020-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $83.07 | 2022-2024 | Gvoke Hypopen |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wietecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.